331 3% (4%)
CARDIAC RHYTHM MANAGEMENT 1,715 1,580 9% 5%
ELECTROPHYSIOLOGY 116 109 7% 4%
CARDIAC RHYTHM MANAGEMENT 1,831 1,689 8% 4%
ENDOSCOPY 710 637 11% 6%
UROLOGY 318 295 8% 6%
ENDOSURGERY 1,028 932 10% 6%
NEUROMODULATION 177 143 24% 23%
DIVESTED BUSINESSES 62 407 N/A N/A
WORLDWIDE $6,048 $6,204 (3%) (7%)
Growth rates are based on actual, non-rounded amounts.
BOSTON SCIENTIFIC CORPORATION
NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS
(Unaudited)
Q3 2008 Net Sales as compared to Q3 2007
Estimated
Change Impact
As Reported Constant of Foreign
Currency Basis Currency Basis Currency
In millions
DOMESTIC $14 $14
EMEA 46 15 31
INTER-CONTINENTAL (9) (32) 23
INTERNATIONAL 37 (17) 54
DIVESTED BUSINESSES (121) (121)
WORLDWIDE $(70) $(124) $54
Q3 2008 Net Sales as compared to Q3 2007
Estimated
'/>"/>SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Related biology technology :1.
Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet2.
Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders3.
Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent4.
Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels5.
Boston Scientific to Participate in UBS Global Life Sciences Conference6.
Boston Scientific Announces Court Decision7.
IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts8.
InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th9.
NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program10.
TechCFO Adds Gary Strickland as Partner in Boston Office11.
Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System